NAMS NewAmsterdam Pharma Co N.V. Insider Trading

Louise Frederika Kooij (CAO) sells 40,000 shares at $30.20 avg for $1.2M via scheduled 10b5-1 plan at NAMS

Louise Frederika Kooij, Chief Accounting Officer, executed 2 separate sales totaling 40,000 shares for $1,208,159.00 on 2026-06-22 under a pre-arranged 10b5-1 trading plan. Her non-derivative holdings declined from 64,353 to 24,353 shares, a reduction of 62.2%. The company is unprofitable with net income of $-48,441,000.00 in the latest quarter and annual revenue growth of -50.6%. The stock is currently trading at $32.63, above the blended sale price of $30.20 but down 22.7% from its 52-week high of $42.20. Kooij's prior sales at this ticker show mixed outcomes: 30-day returns ranged from +4.7% to +11.5%, while 90-day returns were consistently negative, ranging from -6.6% to -11.2%.

CAO Louise Kooij sells 65,000 NAMS shares at $35.69 under 10b5-1 plan; retains 24,353 non-derivative shares plus 148,149 derivative holdings

Louise Frederika Kooij, Chief Accounting Officer, sold 65,000 shares (65.0K shares) valued at $2,319,850.00 ($2.3M) on 2026-05-26 at $35.69 per share as part of a pre-arranged 10b5-1 trading plan. After this scheduled sale, she retains 24,353 shares (24.4K shares) in non-derivative holdings, with an additional 148,149 shares held through derivative securities (80,015 options and 68,134 options), meaning her overall position remains substantial. Her prior five trades at NAMS show a pattern of sales with 30-day returns ranging from +4.7% to +11.5% followed by 90-day declines ranging from -5.9% to -11.2%, suggesting post-sale price weakness has historically occurred within her trading window at this ticker. The company reports negative net income of $-48,441,000.00 ($-48.4M), annual revenue decline of -50.6%, and current revenue of only $3,040,000.00 ($3.0M), indicating material operational challenges that may inform the scheduled nature of this divestment.

Director Lange sold 44,619 shares (81.2% of holdings) at $30.42 avg; stock down 28.1% from 52-week high, revenues fallen 50.6%.

Louis G. Lange, a Director, executed 2 separate sales totaling 44,619 shares for $1,357,229.51, reducing his holding from 54,979 shares to 10,360 shares—a reduction of 81.2%. The sales occurred at blended average price of $30.42, above the current price of $29.82 but notably below the 52-week high of $41.45. NewAmsterdam Pharma is trading 28.1% below its 52-week peak, with revenue declining 50.6% year-over-year and the company reporting a net loss of $72,005,000 in its most recent full fiscal year. While Lange's cross-ticker track record shows 100% 90-day win rate on prior buys, his single prior trade at NAMS in February 2024 resulted in a 6.4% 90-day return, providing limited predictive value for sell-side timing at this specific security. The near-complete liquidation of his NAMS position warrants investor attention given the company's deteriorating operational metrics and depressed valuation context.

Chief Scientific Officer Kastelein sold 300,000 shares for $9.1M over 3 days at $30.30 blended average under 10b5-1 plan

Kastelein executed 3 separate sales totaling 300,000 shares for $9,090,868.39 across March 5–9, 2026, reducing his holdings by 81.2% from 369.3K to 69.3K shares. The sales were conducted under a pre-arranged 10b5-1 trading plan, indicating they were scheduled rather than discretionary. As Chief Scientific Officer, this substantial reduction in his equity stake warrants investor attention to understand whether the plan was established during a different market environment or reflects a planned liquidity event unrelated to near-term business outlook.

CEO Michael H. Davidson sold 443,707 shares of NAMS at $33.25 (2026-03-02); post-sale holds 174,144 shares (28.2% of prior holdings).

CEO Michael H. Davidson sold 443,707 shares at $33.25 on 2026-03-02, reducing his stake from 617,851 shares to 174,144 shares, representing a -71.8% reduction in holdings. The sale occurred at $33.25, slightly above the current price of $32.83 but well below the 52-week high of $41.45; the stock has declined -14.4% over the prior 90 days. The underlying company posted revenue of $348,000.00 in the latest quarter, net income of $-72,005,000.00, and annual revenue growth of -50.6%, signaling severe operational distress. In his cross-ticker track record, Davidson's 7 prior sells had a 0 of 0 well-timed rate at the 90-day mark, and his 5 most recent trades at NAMS (all sales within 6 days) have measurable outcomes not yet determinable. The rapid succession of five sales within one week, the substantial reduction in personal exposure, combined with sharply negative fundamentals, warrants examination of whether this represents a shift in the insider's confidence in near-term trajectory.

CEO Davidson sold 306,293 shares (63.8% of holdings) across 7 transactions for $10.6M; pre-arranged 10b5-1 plan

Michael H. Davidson, Chief Executive Officer of NewAmsterdam Pharma Co N.V., executed 7 separate sales totaling 306,293 shares for $10,575,091.20 between 2026-02-24 and 2026-02-26 at prices ranging from $33.63 to $36.68 per share (blended average $34.53). This represents a reduction of 306,293 shares from his pre-transaction holdings of 480,437 shares, leaving him with 174,144 shares post-transaction. The sales are part of a pre-arranged 10b5-1 trading plan, meaning they are scheduled and not discretionary transactions. The magnitude of this divestiture—reducing his stake by 63.8% over three trading days—represents a substantial shift in his equity ownership at the company.

NewAmsterdam Pharma CSO sold 45,481 shares at blended $35.31 average (Feb 20) for $1.6M; holds 53.5K post-transaction.

Kastelein Johannes Jacob Pieter, Chief Scientific Officer, executed 2 separate sales totaling 45,481 shares for $1,605,997.94 on 2026-02-20, reducing holdings by -45.9% from 98,981 to 53,500 shares. This represents a material reduction in CSO equity stake at a company facing structural headwinds: quarterly revenue of $348,000.00 with negative net income of $-72,005,000.00, and annual revenue decline of -50.6% year-over-year. Regarding timing, his same-ticker history at NAMS shows 3 of 4 prior sells (August 2025 and March 2024) were followed by 30-day gains of 4.7% to 9.9%, indicating those prior dispositions were poorly timed against subsequent price appreciation. The current sale occurred at $35.31 against a 52-week high of $41.45 (-13.1% from peak), with the stock showing +8.1% 30-day momentum but -13.1% 90-day return. The combination of substantial share reduction by a senior scientific officer, alongside severe revenue contraction and operating losses, presents a noteworthy signal for investors to assess whether the CSO's divestiture reflects information asymmetry about the commercial trajectory or product viability.

NewAmsterdam CAO sold 72,428 shares for $2.3M in two sales (Jan 27–28) at $32.25 avg, reducing holdings by 74.8%

Louise Frederika Kooij, Chief Accounting Officer of NewAmsterdam Pharma Co N.V., executed 2 separate sales totaling 72,428 shares for $2,335,859.52 at an average price of $32.25. This liquidation reduced her holdings from 96,781 shares to 24,353 shares, a 74.8% reduction. The sales occurred on 2026-01-27 and 2026-01-28 at transaction prices of $32.62 and $31.80, both above the current price of $31.44 but within the 52-week range of $14.90–$41.45. The company is unprofitable (net income of $-72,005,000.00 over its most recent full fiscal year) despite strong revenue growth of 223.4% year-over-year. At the same ticker, Kooij executed 4 prior sales in January 2026 (on 2026-01-23 and 2026-01-26, outcomes not yet measurable), and 1 sale on 2025-12-26 that showed a 30-day return of -5.6%, none measuring well-timed at the 90-day horizon. Her cross-ticker track record shows a 33.33% well-timed rate on 10 prior sells with an average 90-day return of 23.7% (indicating those prior sales were followed by stock gains, not losses)—a pattern inconsistent with successful sell-side timing.

NAMS Chief Accounting Officer sells 72,572 shares for $2.4M under scheduled 10b5-1 plan; holdings cut from 96.9K to 24.4K shares

Kooij Louise Frederika executed 4 separate sales totaling 72,572 shares for $2,415,843.11 on 2026-01-23 and 2026-01-26 at prices ranging from $32.77 to $34.37, reducing her holdings by 74.9% from 96,925 shares to 24,353 shares. The transaction is scheduled under a pre-arranged 10b5-1 trading plan, indicating this sale was not a discretionary decision but rather part of a predetermined portfolio management arrangement. The substantial reduction in her direct ownership stake—from approximately 96.9K to 24.4K shares—represents a material shift in her equity position at the company. This scale of liquidation, while executed through a scheduled mechanism, results in significantly diminished financial exposure to NewAmsterdam Pharma's future performance.

CFO Mayur Ian executes 5 scheduled sales totaling 100,000 shares for $3,260,617.98 under 10b5-1 plan

Somaiya Mayur Ian, CFO of NewAmsterdam Pharma, executed 5 separate sales on 2026-01-20 and 2026-01-21 totaling 100,000 shares for $3,260,617.98 at blended average price of $32.61. This reduction represents -63.1% of his pre-transaction holdings of 158,382 shares, leaving him with 58,382 shares post-transaction. The sales were conducted under a pre-arranged 10b5-1 trading plan, meaning they were scheduled in advance rather than discretionary decisions timed to current market conditions. While the magnitude of the position reduction is substantial, the scheduled nature of the transaction limits what can be inferred about current executive conviction regarding the stock's valuation.